ArticleEuropean journal of nuclear medicine and molecular imaging2026
Baseline body composition and early PRRT outcome in GEP-NETs: an exploratory analysis.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeEarly progression after PRRT occurs in a subset of patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Associations between body composition and early PET-based progression after PRRT were assessed.
methodsIn this retrospective analysis, 321 patients undergoing PRRT were screened. Body composition parameters were assessed on the CT component at the L3/L4 level. Myosteatosis was defined using BMI-adjusted psoas muscle attenuation cut-offs. The primary endpoint was early SSTR-targeted PET-based progression after up to four consecutive PRRT cycles, dichotomized as progressive disease versus disease control, which was available in 301 patients.
resultsEarly PET-based progression occurred in 24/301 patients (8.0%). Traditional quantity-based body composition parameters were not associated with early progression. Baseline myosteatosis was present in only 8/301 patients (2.7%) and showed a nominal association with early progression in univariable analysis (OR 7.8, 95% CI 1.74-34.78; p = 0.0073), but this association did not remain significant after Benjamini-Hochberg correction for multiple testing (FDR-adjusted p = 0.1073). In a separately specified baseline-adjusted model, myosteatosis remained nominally associated with early progression (OR 8.1, 95% CI 1.69-38.75; p = 0.0090). In an exploratory model additionally including the number of completed PRRT cycles as a post-baseline treatment-exposure variable, the association was attenuated and narrowly missed conventional statistical significance (OR 5.7, 95% CI 0.97-32.86; p = 0.0538).
conclusionTraditional quantity-based body composition parameters were not associated with early PET-based progression after PRRT. Although baseline myosteatosis showed a nominal association with early progression, this finding was based on only eight patients and did not remain significant after correction for multiple testing. The results should therefore be regarded as exploratory and hypothesis-generating and do not establish clinical utility of myosteatosis for individual risk stratification.
Indexed as
Identifiers
42749936What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.